Gemcitabine and carboplatin in carcinoma of unknown primary site: a phase 2 Adelaide Cancer Trials and Education Collaborative study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Gemcitabine and carboplatin in carcinoma of unknown primary site: a phase 2 Adelaide Cancer Trials and Education Collaborative study

Published:2006-10-31 Issue:10 Volume:95 Page:1309-1313
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Pittman K B, ,Olver I N,Koczwara B,Kotasek D,Patterson W K,Keefe D M,Karapetis C S,Parnis F X,Moldovan S,Yeend S J,Price T J

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/6603440.pdf

Reference16 articles.

1. Briasoulis E, Kalofonos H, Bafaloukas D, Samantas E, Fountzilas G, Xiros N, Christodoulou C, Kosmidis P (2000) Carboplatin plus paclitaxel in unknown primary cancer: a phase 2 Hellenic co-operative oncology group study. J Clin Oncol 18: 3101–3107

2. Calvert H, Newell D, Gumbrell L (1989) Carboplatin dosage: a prospective evaluation of a simple formula based upon renal function. J Clin Oncol 7: 1748–1756

3. Culine S, Kramar A, Saghatchian M, Bugat R, Lesimple T, Lortholary A, Merrouche Y, Laplanche A, Fizari K (2002) Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of unknown primary site. J Clin Oncol 20: 4679–4683

4. Culine S, Loertholary A, Voigt J, Bugat R, Theodore C, Priou F, Kaminsky M, Lesimple T, Pivot X, Coudert B, Douillard J, Merrouche Y, Allouache A, Goupil A, Negrier S, Viala J, Petrow P, Bouzy J, Laplanche A, Fizazi K (2003) Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomised phase II study – Trial of the French Study Group on carcinomas of unknown primary (GEFCAPI). J Clin Oncol 21: 3479–3482

5. Fleming TR (1982) One-sample multiple testing procedure for phase II clinical trials. Biometrics 38: 143–151

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Enhancer mutations modulate the severity of chemotherapy-induced myelosuppression;Life Science Alliance;2024-01-16

2. CUP-Syndrom;Therapie-Handbuch - Onkologie und Hämatologie;2024

3. Case Report: Combined pembrolizumab, 5-fluorouracil, and cisplatin therapy were remarkably effective in p16-positive squamous cell carcinoma of unknown primary;Frontiers in Oncology;2023-07-10

4. Neoplasms of Unknown Primary Site;Holland‐Frei Cancer Medicine;2022-10-21

5. CUP-Syndrom;Therapie-Handbuch - Onkologie und Hämatologie;2022

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3